Tolvaptan

• CAT Number: A000286
• CAS Number: 150683-30-0
• Molecular Formula: C26H25ClN2O3
• Molecular Weight: 448.9
• Purity: ≥95%
• Target: Vasopressin Receptor
• Solubility: >17.8mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
• InChIKey: GYHCTFXIZSNGJT-UHFFFAOYSA-N
• SMILES: CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C

Tolvaptan is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009.

Reference

1: Humayun MA, Cranston IC. In-patient Tolvaptan use in SIADH: care audit,
therapy observation and outcome analysis. BMC Endocr Disord. 2017 Nov 6;17(1):69.
doi: 10.1186/s12902-017-0214-2. PubMed PMID: 29110656.

2: Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J,
McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J
Med. 2017 Nov 4. doi: 10.1056/NEJMoa1710030. [Epub ahead of print] PubMed PMID:
29105594.

3: Ingelfinger JR. Tolvaptan and Autosomal Dominant Polycystic Kidney Disease. N
Engl J Med. 2017 Nov 4. doi: 10.1056/NEJMe1714276. [Epub ahead of print] PubMed
PMID: 29105553.

4: Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, Omote T, Kikuchi
A, Ishikawa M, Amitani K, Takahashi N, Maruyama Y, Imura H, Shimizu W. Effects of
tolvaptan on urine output in hospitalized heart failure patients with
hypoalbuminemia or proteinuria. Heart Vessels. 2017 Oct 23. doi:
10.1007/s00380-017-1066-4. [Epub ahead of print] PubMed PMID: 29063302.

5: Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y. Tolvaptan promotes
urinary excretion of sodium and urea: a retrospective cohort study. Clin Exp
Nephrol. 2017 Oct 20. doi: 10.1007/s10157-017-1475-9. [Epub ahead of print]
PubMed PMID: 29052786.

6: Mizuno H, Hoshino J, Suwabe T, Sumida K, Sekine A, Oshima Y, Oguro M, Kunizawa
K, Kawada M, Hiramatsu R, Hayami N, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K,
Ubara Y. Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease. Case
Rep Nephrol Dial. 2017 Jul 19;7(3):108-111. doi: 10.1159/000477664. eCollection
2017 May-Aug. PubMed PMID: 29034246; PubMed Central PMCID: PMC5624279.

7: Mosedale M, Eaddy JS, Trask OJ Jr, Holman NS, Wolf KK, LeCluyse E, Ware BR,
Khetani SR, Lu J, Brock WJ, Roth SE, Watkins PB. miR-122 Release in Exosomes
Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte
Micropatterned Coculture Model. Toxicol Sci. 2017 Sep 28. doi:
10.1093/toxsci/kfx206. [Epub ahead of print] PubMed PMID: 29029277.

8: Nakai M, Ogawa K, Takeda R, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J,
Sho T, Suda G, Morikawa K, Sakamoto N. Increased serum C-reactive protein and
decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan
in patients with liver cirrhosis. Hepatol Res. 2017 Oct 6. doi:
10.1111/hepr.12988. [Epub ahead of print] PubMed PMID: 28984014.

9: Carreño A, Hernández B, Mayoralas á, Calle C. Syndrome of inappropriate
secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light
chain multiple mieloma. Treatment with tolvaptan. Nefrologia. 2017 Sep –
Oct;37(5):558-559. doi: 10.1016/j.nefro.2016.10.015. English, Spanish. PubMed
PMID: 28946972.

10: Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N,
Hashimoto E, Tokushige K. The Outcome of Cirrhotic Patients with Ascites is
Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Intern Med.
2017 Sep 25. doi: 10.2169/internalmedicine.9033-17. [Epub ahead of print] PubMed
PMID: 28943585.